The committee recognised the uncertainties in the published evidence but concluded that using iFuse to treat chronic sacroiliac pain is likely to lead to less pain, reduced disability and a better ...

Electronic cigarettes have the potential to be the future of the tobacco industry. Although they've experienced a growth in popularity in a relatively short period of time, e-cigs still need to ...

SANTA CLARA, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic ...

In April 2021, SI-BONE® launched the iFuse-TORQ™ Implant System for the treatment of pelvic fractures, and for SI joint fusion. 1. The U.S. pelvic fracture market includes as many as 120,000 patients ...

SI-BONE, Inc. SIBN announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT Implant System (TNT), on Thursday. TNT received the FDA’s 510(k) clearance and was ...

SI-Bone's innovative titanium implants, including the iFuse system, address sacroiliac joint dysfunction, pelvic trauma, and spinal stability, with significant market adoption and FDA approvals.

A U.S. Dept. of Justice probe into Medtronic Inc.’s (NYSE:MDT) marketing practices for its Infuse bone growth product line is growing, according to a report in the New York Times. The Old Grey Lady ...